TRANCE is a TNF family member that regulates dendritic cell and osteoclast function

Journal of Leukocyte Biology

Volumn 65, Issue 6, 1999, Pages 715-724

  Wong, Brian R ^a   Josien, Régis ^a   Choi, Yongwon ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Cytokines; T cells; TRAIL

Indexed keywords

COLECALCIFEROL; CYTOKINE; DEXAMETHASONE; PARATHYROID HORMONE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; BONE DEVELOPMENT; CELL FUNCTION; CONTROLLED STUDY; DENDRITIC CELL; HOMEOSTASIS; IMMUNE SYSTEM; IMMUNOREGULATION; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALIA;

EID: 0000371126     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlb.65.6.715     Document Type: Review

References (75)

1. Hahne, M., Kataoka, T., Schreter, M., Hofmann, K., Irmler, M., Bodmer, J. L., Schneider, P., Bornand, T., Holler, N., French, L. E., Sordat, B., Rimoldi, D., Tschopp, J. (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J. Exp. Med. 188, 1185-1190.
2. Mauri, D. N., Ebner, R., Montgomery, R. I., Kochel, K. D., Cheung, T. C., Yu, G. L., Ruben, S., Murphy, M., Eisenberg, R. J., Cohen, G. H., Spear, P. G., Ware, C. F. (1998) LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 8, 21-30.
3. Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S., 3rd, Frankel, W. N., Lee, S. Y., Choi, Y. (1997) TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272, 25190-25194.
4. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., Galibert, L. (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179.
5. 2, or parathyroid hormone in the microenvironment of bone. Biochem. Biophys. Res. Commun. 246, 337-341.
6. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., Boyle, W. J. (1998) Osteoprotegerin ligand is a cytokine that regulates osteotclast differentiation and activation. Cell 93, 165-176.
7. Chicheportiche, Y., Bourdon, P. R., Xu, H., Hsu, Y. M., Scott, H., Hession, C., Garcia, I., Browning, J. L. (1997) TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem. 272, 32401-32410.
8. Smith, C. A., Farrah, T., Goodwin, R. G. (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76, 959-962.
9. Nocentini, G., Giunchi, L., Ronchetti, S., Krausz, L. T., Bartoli, A., Moraca, R., Migliorati, G., Riccardi, C. (1997) A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. Proc. Natl. Acad. Sci. USA 94, 6216-6221.
10. Pan, G., Ni, J., Wei, Y. F., Yu, G., Gentz, R., Dixit, V. M. (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL [see comments]. Science 277, 815-818.
11. Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., Goddard, A. D., Godowski, P., Ashkenazi, A. (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors [see comments]. Science 277, 818-821.
12. Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C. P., DuBose, R. F., Goodwin, R. G., Smith, C. A. (1997) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186, 1165-1170.
13. Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., Goodwin, R. G. (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7, 813-820.
14. Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., Ashkenazi, A. (1997) A novel receptor for Apo2I/TRAIL contains a truncated death domain. Curr Biol. 7, 1003-1006.
15. Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., Nagata, S. (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314-317.
16. Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T., Nagata, S. (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76, 969-976.
17. Nagata, S., Suda, T. (1995) Fas and Fas ligand: lpr and gld mutations. Immunol. Today 16, 39-43.
18. Damay, B. G., Aggarwal, B. B. (1997) Early events in TNF signaling: a story of associations and dissociations. J. Leukoc. Biol. 61, 559-566.
19. Rao, A., Luo, C., Hogan, P. G. (1997) Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15, 707-747.
20. Yang, X., Khosravi-Far, R., Chang, H. Y., Baltimore, D. (1997) Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 89, 1067-1076.
21. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., Greenberg, M. E. (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326-1331.
22. Verheij, M., Bose, R., Lin, X. H., Yao, B., Jarvis, W. D., Grant, S., Birrer, M. J., Szaho, E., Zon, L. I., Kyriakis, J. M., Haimovitz-Friedman, A., Fuks, Z., Kolesnick, R. N. (1996) Requirement for ceramide-initiated SAPK/ JNK signalling in stress-induced apoptosis. Nature 380, 75-79.
23. Goillot, E., Raingeaud, J., Ranger, A., Tepper, R. I., Davis, R. J., Harlow, E., Sanchez, I. (1997) Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. Proc. Natl. Acad. Sci. USA 94, 3302-3307.
24. Natoli, G., Costanzo, A., Ianni, A., Templeton, D. J., Woodgett, J. R., Balsano, C., Levrero, M. (1997) Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science 275, 200-203.
25. Liu, Z. G., Hsu, H., Goeddel, D. V., Karin, M. (1996) Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87, 565-576.
26. Lewit-Bentley, A., Fourme, R., Kahn, R., Prange, T., Vachette, P., Tavernier, J., Hauquier, G., Niers, W. (1988) Structure of tumour necrosis factor by X-ray solution scattering and preliminary studies by single crystal X-ray diffraction. J. Mol. Biol. 199, 389-392.
27. Jones, E. Y., Stuart, D. I., Walker, N. P. (1992) Crystal structure of TNF. Immunol. Ser. 56, 93-127.
28. Wong, B. R., Josien, R., Lee, S. Y., Sauter, B., Li, H. L., Steinman, R. M., Choi, Y. (1997) TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186, 2075-2080.
29. + memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex. J. Exp. Med. 181, 1293-1301.
30. Foy, T. M., Aruffo, A., Bajorath, J., Buhlmann, J. E., Noelle, R. J. (1996) Immune regulation by CD40 and its ligand GP39. Annu. Rev. Immunol. 14, 591-617.
31. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone. T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, W., Campbell, P., Boyle, W. J., et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [see comments]. Cell 89, 309-319.
32. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N., Suda, T. (1998) Osteoclast differentiation factor is a ligand for osleoprotegerin/osteoclasto-genesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95, 3597-3602.
33. Fuller, K., Wong, B., Fox, S., Choi, Y., Chambers, T. J. (1998) TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med. 188, 997-1001.
34. Juppner, H., Abou-Samra, A. B., Freeman, M., Kong, X. F., Schipani, E., Richards, J., Kolakowski, L. F., Jr., Hock, J., Potts, J. T., Jr., Kronenberg, H. M., et al. (1991) A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 254, 1024-1026.
35. Gedrich, R. W., Gilfillan, M. C., Duckett, C. S., Van Dongen, J. L., Thompson, C. B. (1996) CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J. Biol. Chem. 271, 12852-12858.
36. Lee, S. Y., Lee, S. Y., Kandala, G., Liou, M. L., Liou, H. C., Choi, Y. (1996) CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. Proc. Natl. Acad. Sci. USA 93, 9699-9703.
37. Pullen, S. S., Miller, H. G., Everdeen, D. S., Dang, T. T. A., Crute, J. J., Kehry, M. R. (1998) CD40-lumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 37, 11836-11845.
38. Tomoyasu, A., Goto, M., Fujise, N., Mochizuki, S., Yasuda, H., Morinaga, T., Tsuda, E., Higashio, K. (1998) Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochem. Biophys. Res. Commun. 245, 382-387.
39. Tsuda, E., Higashio, K. (1998) Osteoclastogenesis inhibitory factor (OCIF)/ OPG. Nippon Rinsho 56, 1435-1439.
40. Yamaguchi, K., Kinosaki, M., Goto, M., Kobayashi, F., Tsuda, E., Morinaga, T., Higashio, K. (1998) Characterization of structural domains of human osteoclastogenesis inhibitory factor. J. Biol. Chem. 273, 5117-5123.
41. Huang, B., Eberstadt, M., Olejniczak, E. T., Meadows, R. P., Fesik, S. W. (1996) NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature 384, 638-641.
42. Banchereau, J., Steinman, R. M. (1998) Dendritic cells and the control of immunity. Nature 392, 245-252.
43. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J. Exp. Med. 184, 695-706.
44. + bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J. Immunol. 154, 5851-5861.
45. van Kooten, C., Banchereau, J. (1997) Functions of CD40 on B cells, dendritic cells and other cells. Curr. Opin. Immunol. 9, 330-337.
46. + hematopoietic progenitors induces their proliferation and differentiation into functional dendritic cells. J. Exp. Med. 185, 341-349.
47. Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Van Kooten, C., Durand, I., Banchereau, J. (1994) Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180, 1263-1272.
48. Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., Alber, G. (1996) Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184, 747-752.
49. Ludewig, B., Graf, D., Gelderblom, H. R., Becker, Y., Kroczek, R. A., Pauli, G. (1995) Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. Eur. J. Immunol. 25, 1943-1950.
50. Heufler, C., Koch, F., Stanzl, U., Topar, G., Wysoeka, M., Trinchieri, G., Enk, A., Steinman, R. M., Romani, N., Schuler, G. (19961 Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur. J. Immunol. 26, 659-668.
51. de Saint-Vis, B., Fugier-Vivier, I., Massacrier, C., Gaillard, C., Vanbervliet, B., Ait-Yahia, S., Banchereau, J., Liu, Y. J., Lebecque, S., Caux, C. (1998) The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. J. Immunol. 160, 1666-1676.
52. Ohshima, Y., Tanaka, Y., Tozawa, H., Takahashi, Y., Maliszewski, C., Delespesse, G. (1997) Expression and function of OX40 ligand on human dendritic cells. J. Immunol. 159, 3838-3848.
53. - T lymphocytes by 4-IBB ligand. J. Immunol. 158, 551-559.
54. Grewal, I. S., Flavell, R. A. (1998) CD40 and CDI54 in cell-mediated immunity. Annu. Rev. Immunol. 16, 111-135.
55. Lagresle, C., Mondiere, P., Bella, C., Krammer, P. H., Defrance, T. (1996) Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO-1/Fas-mediated apoptosis. J. Exp. Med. 183, 1377-1388.
56. Lens, S. M., Tesselaar, K., den Drijver, B. F., van Oers, M. H., van Lier, R. A. (1996) A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death. J. Immunol. 156, 507-514.
57. Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., Boyle, W. J., Simonet, W. S. (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268.
58. Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., Sato, Y., Nakagawa, N., Yasuda, H., Mochizuki, S., Gomibuchi, T., Yano, K., Shima, N., Washida, N., Tsuda, E., Morinaga, T., Higashio, K., Ozawa, H. (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247, 610-615.
59. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S. I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., Kanno, T., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K. (1998) Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329-1337.
60. Takai, H., Kanematsu, M., Yano, K., Tsuda, E., Higashio, K., Ikeda, K., Watanabe, K., Yamada, Y. (1998) Transforming growth factor-beta stimulates the production of Osteoprotegerin/Osteoclastogenesis inhibitory factor by bone marrow stromal cells. J. Biol. Chem. 273, 27091-27096.
61. Weih, F., Carrasco, D., Durham, S. K., Barton, D. S., Rizzo, C. A., Ryseck, R. P., Lira, S. A., Bravo, R. (1995) Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 80, 331-340.
62. Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D. P., Gabrilovich, D. I. (1998) Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 160, 1224-1232.
63. Iotsova, V., Caamano, J., Loy, J., Yang, Y., Lewin, A., Bravo, R. (1997) Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2 [see comments]. Nature Med. 3, 1285-1289.
64. Jimi, E., Nakamura, I., Ikebe, T., Akiyama, S., Takahashi, N., Suda, T. (1998) Activation of NF-kappaB is involved in the survival of osteoclasts promoted by interleukin-1. J. Biol. Chem. 273, 8799-8805.
65. Baeuerle, P. A., Baltimore, D. (1988) NF-κB. Science 242, 540-546.
66. Darnay, B. G., Haridas, V., Ni, J., Moore, P. A., Aggarwal, B. B. (1998) Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-jun N-terminal kinase. J. Biol. Chem. 273, 20551-20555.
67. Wong, B. R., Josien, R., Lee, S. Y., Vologodskaia, M., Steinman, R. M., Choi, Y. (1998) The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J. Biol. Chem. 273, 28355-28359.
68. Lee, S. Y., Lee, S. Y., Choi, Y. (1997) TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. J. Exp. Med. 185, 1275-1285.
69. Grigoriadis, A. E., Wang, Z. Q., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, H. A., Wagner, E. F. (1994) c-Fos: a key regulator of osteoclastmacrophage lineage determination and bone remodeling. Science 266, 443-448.
70. Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., Dodds, R. A., James, I. E., Rosenberg, M., Lee, J. C., Young, P. R. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363-14367.
71. Golstein, P. (1997) Cell death: TRAIL and its receptors. Curr. Biol. 7. R750-R753.
72. Young, J. W., Inaba, K. (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity [comment]. J. Exp. Med. 183, 7-11.
73. + T-helper and a T-killer cell [see comments]. Nature 393, 474-478.
74. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R., Melief, C. J. (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions [see comments]. Nature 393, 480-483.
75. Bennett, S. R., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F., Heath, W. R. (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling [see comments]. Nature 393, 478-480.